ArticlePediatric pulmonology2021
COVID-19 and multisystem inflammatory syndrome in children: A systematic review and meta-analysis.
Article in Pediatric pulmonology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 5 syntheses or guidelines pooled it, 195 citations in OpenAlex.
- Multisystem inflammatory syndrome in children: an Umbrella review.Journal of anesthesia · 2024Pooled it
- Evidence linking COVID-19 and the health/well-being of children and adolescents: an umbrella review.BMC medicine · 2024Pooled it
- Longitudinal Cardiac Outcomes of Multisystem Inflammatory Syndrome in Children: A Systematic Review and Meta-Analysis.Pediatric cardiology · 2023Pooled it
- Guidelines for the prevention and management of children and adolescents with COVID-19.European journal of pediatrics · 2022Guideline
- Pooled it
- Booster vaccination using bivalent DS-5670a/b is safe and immunogenic against SARS-CoV-2 variants in children aged 5-11 years: a phase 2/3, randomized, active-controlled study.Frontiers in immunology · 2024Trial
- Research Progress on Coronary Artery Injury and Myocardial Ischemia in Multisystem Inflammatory Syndrome in Children.Current issues in molecular biology · 2026Review
- MIS-C: Diagnosis, Management, and Outcomes.Open forum infectious diseases · 2026Review
- Vaccine Hesitancy and Refusal Among Parents of Children Aged 5-11 Years: Evidence from the COVID-19 Pandemic in the Calabria Region.Vaccines · 2025Article
- Factors Associated with COVID-19 Infection Related Multisystem Inflammatory Syndrome in Children: A Multicenter Matched Case-Control Study.Children (Basel, Switzerland) · 2025Article
- Cardiovascular involvement in multisystem inflammatory syndrome in children and midterm follow-up from a pediatric tertiary center in India.World journal of clinical pediatrics · 2025Article
- Comparison of Cardiac Findings in Pediatric Patients with Multisystem Inflammatory Syndrome in Children Associated with COVID-19.Sisli Etfal Hastanesi tip bulteni · 2025Article
- Comparing clinical and biochemical characteristics of febrile seizures in children with and without COVID-19: a retrospective study.BMC infectious diseases · 2024Article
- NK Cell and Monocyte Dysfunction in Multisystem Inflammatory Syndrome in Children.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Clinical Features and Outcomes of Pediatric and Adult Patients Hospitalized for Coronavirus Disease 2019: A Comparison Across Age Strata.Open forum infectious diseases · 2024Article
- Long-term surveillance of SARS-CoV-2 in the school community from Campo Grande, Brazil.BMC public health · 2024Article
- The evaluation of the burden of multisystem inflammatory syndrome in children on health economics.Archives of rheumatology · 2024Article
- [Multisystem inflammatory syndrome in children in the context of coronavirus disease 2019 pandemic].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2024Review
- Multisystem inflammatory syndrome in 1.2 million children: longitudinal cohort study of risk factors.Pediatric research · 2024Article
- Multisystem Inflammatory Syndrome in Children after Coronavirus Disease 2019 and Its Cytokine Storms.Reviews in cardiovascular medicine · 2023Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
- Comment on
Authors and funding
5 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 has been increasingly recognized. However, the clinical features of MIS-C and the differences from Kawasaki disease remain unknown. The study aims to investigate the epidemiology and clinical course of MIS-C.
methodsPubMed and EMBASE were searched through August 30, 2020. Observational studies describing MIS-C were included. Data regarding demographic features, clinical symptoms, laboratory, echocardiography and radiology findings, treatments, and outcomes were extracted. Study-specific estimates were combined using one-group meta-analysis in a random-effects model.
resultsA total of 27 studies were identified including 917 MIS-C patients. The mean age was 9.3 (95% confidence interval [CI], 8.4-10.1). The pooled proportions of Hispanic and Black cases were 34.6% (95% CI, 28.3-40.9) and 31.5% (95% CI, 24.8-38.1), respectively. The common manifestations were gastrointestinal symptoms (87.3%; 95% CI, 82.9-91.6) and cardiovascular involvement such as myocardial dysfunction (55.3%; 95% CI, 42.4-68.2), coronary artery aneurysms (21.7%; 95% CI, 12.8-30.1) and shock (65.8%; 95% CI, 51.1-80.4), with marked elevated inflammatory and cardiac markers. The majority of patients received intravenous immunoglobulin (81.0%; 95% CI, 75.0-86.9), aspirin (67.3%; 95% CI, 48.8-85.7), and corticosteroids (63.6%; 95% CI, 53.4-73.8) with a variety of anti-inflammatory agents. Although myocardial dysfunction improved in 55.1% (95% CI, 33.4-76.8) at discharge, the rate of extracorporeal membrane oxygenation use was 6.3% (95% CI, 2.8-9.8) and the mortality was 1.9% (95% CI, 1.0-2.8).
conclusionOur findings suggest that MIS-C leads to multiple organ failure, including gastrointestinal manifestations, myocardial dysfunction and coronary abnormalities, and has distinct features from Kawasaki disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.